According to the announcement made by Yuanda Pharmaceutical on the evening of July 17, the company's first nasal spray product for increasing tear secretion in patients with dry eye syndrome, Varenicline Tartrate Nasal Spray (OC-01), has been officially approved and implemented the first batch of commercial prescriptions in mainland China at the First Affiliated Hospital of Sun Yat-sen University and Shenzhen Eye Hospital. This marks that the only nasal spray product currently approved for increasing tear secretion in patients with dry eye syndrome in China has officially entered clinical application.

It is disclosed that dry eye is a common chronic ocular surface disease in clinical practice. The incidence of dry eye in China is about 21%-30%, and the number of dry eye patients is conservatively estimated to be about 360 million. At present, dry eye patients visiting outpatient clinics in medical institutions account for more than 30% of the total number of ophthalmology patients. It is expected that in the next 5-10 years, this proportion may rise to 40%. Dry eye has become an important social public health issue affecting national health.

The announcement shows that OC-01 adopts an innovative nasal administration method, which significantly improves the natural tear secretion of patients with dry eye, improves the stability of the tear film, and blocks the vicious cycle of dry eye pathophysiology. At the same time, OC-01 only needs to be administered by nasal spray twice a day, which is easy to use and can avoid the cumbersome use of traditional eye drops, which is expected to improve patient compliance. This product is expected to provide a new treatment option for patients with dry eye that is well tolerated and has a definite effect.

Yuanda Pharmaceutical said that the company has taken the field of ophthalmology as one of its important strategic development directions. At present, the company has built a "specialized, full-range, multi-variety" innovative drugThe company has a drug product system that includes a number of global innovative products for the treatment of "myopia", "dry eyes", "pterygium", "anti-inflammatory and analgesic treatment after ophthalmic surgery", "demodex blepharitis" and "meibomian gland dysfunction caused by demodex", and has made significant progress in research and development. In the next three years, a number of innovative products are expected to be approved for marketing.

According to the company's official website, Yuanda Pharmaceutical is a technology-innovative international pharmaceutical company whose core businesses span three major areas: pharmaceutical technology, nuclear medicine anti-tumor diagnosis and treatment, cardiovascular and cerebrovascular precision interventional diagnosis and treatment technology, and biotechnology.

It is worth mentioning that Yuanda Pharmaceutical announced on July 7 that the breakthrough interim data of the DOORwaY90 clinical trial of yttrium [90Y] microsphere injection successfully reached the preset co-primary endpoint, and the FDA formally approved the new indication of the product in advance for the treatment of unresectable hepatocellular carcinoma (HCC), without limiting the size of the tumor diameter. This marks that SIR-Spheres® yttrium [90Y] microsphere injection has become the world's first and only FDA-approved selective internal radiotherapy product for dual indications of unresectable HCC and colorectal cancer liver metastasis.

On the evening of June 4, Yuanda Pharmaceutical announced that the international multi-center Phase III clinical trial of CBT-001 (GPN00153), a globally innovative ophthalmic drug for the treatment of pterygium, has recently completed the enrollment of all patients in global centers.

In the secondary market, on July 17, Yuanda Pharmaceutical closed up 5.13% at HK$9.83 per share. If we extend the time, from May 1 to the close of July 17, Yuanda Pharmaceutical's cumulative increase was more than 64%.

https://finance.eastmoney.com/a/202507183460856570.html